Tirzepatide Outperforms Semaglutide on Combined T2D Goals
Numerous studies have shown that intensive interventions to meet all combined targets significantly reduce cardiovascular events and mortality, Leite noted.
While GLP-1 medications show benefits in each of these measures, the superiority of tirzepatide, a dual GLP-1/ glucose-dependent insulinotropic polypeptide agonist has not been demonstrated in the context of the goal of simultaneously achieving the control of all therapeutic targets. SURPASS-2 Post Hoc Analysis
Leite and colleagues conducted the post hoc analysis of the multicenter, randomized, parallel-group SURPASS-2 trial, involving 1879 patients with T2D that was inadequately controlled with a metformin dose of at least 1500 mg/d.
In the study, patients were randomized to either tirzepatide 5 mg, 10 mg, or 15 mg vs semaglutide 1 mg.
The mean age was 56.6 years, 53% were women, mean A1c was 8.3%, and mean BMI was 34.2. Patients had a median diabetes duration of 7.1 years.
For the primary endpoint of the trial, the change in A1c from baseline to 40 weeks was -2.01, -2.24, and -2.30 percentage points with tirzepatide doses of 5 mg, 10 mg, and 15 mg, respectively, vs -1.86 percentage points with semaglutide, indicating that 'tirzepatide at all doses was noninferior and superior to semaglutide,' the SURPASS-2 authors reported.
For the current analysis, the assessed outcomes were the attainment of standard and intensive therapeutic targets, based on the American Diabetes Association's Standards of Care in Diabetes.
Specifically, standard targets include A1c < 7.0%, blood pressure < 140/90 mm Hg, low-density lipoprotein (LDL) cholesterol < 70 mg/dL, and > 10% weight loss.
The intensive targets are A1c < 6.5%, blood pressure < 130/80 mm Hg, LDL cholesterol < 55 mg/dL, and > 15% weight loss.
At baseline, the mean number of therapeutic targets achieved was 1.1 for standard targets and 0.5 for intensive targets, underscoring the uphill battle patients often face.
Factors associated with having attained more of the goals at baseline included being White, having lower mean A1c and fasting glucose, having lower waist circumference, and having lower blood pressure levels.
By the end of the study, those treated with tirzepatide at all doses achieved more of the standard goals than those treated with semaglutide (2.3, 2.5, and 2.6 with tirzepatide 5, 10, and 15 mg, respectively, vs 2.2 with semaglutide; P < .001).
Likewise, the rates of achieving the intensive goals were higher with tirzepatide (1.5, 1.7, and 1.9 with tirzepatide 5, 10, and 15 mg, respectively, vs 1.3 with semaglutide; P < .001).
Of note, patients on tirzepatide did not have significant differences compared with those on semaglutide in terms of the achievement of blood pressure < 140/90 mm Hg ( P = .13) or LDL cholesterol < 70 mg/dL ( P = .94).
However, the rates of patients achieving three or more standard therapeutic targets were 42%, 53%, and 57% for those treated with tirzepatide at 5, 10, and 15 mg, respectively, vs 35% of those treated with semaglutide (odds ratio [OR] for pooled tirzepatide vs semaglutide, 1.91; P < .001).
And for intensive targets, the corresponding rates for meeting three or more targets were 15%, 20%, and 29% for participants treated with tirzepatide at the 3 doses vs 8% for participants treated with semaglutide (OR, 3.09; P < .001).
'The most pronounced advantages of tirzepatide over semaglutide in this analysis were observed in glycemic control and weight management,' Leite said.
'Modest effects on LDL cholesterol were found with both tirzepatide and semaglutide.'
Commenting on the study, Shylaja Srinivasan, MD, an associate professor of pediatrics and director of the Pediatric Type 2 Diabetes Clinic at the University of California San Francisco, said the findings are consistent with the bulk of research showing improvements with tirzepatide compared with GLP-1s.
'It is not surprising to see the findings as tirzepatide does appear to be more efficacious than semaglutide,' Srinivasan said.
'A key caveat was that the comparisons were with 1 mg of semaglutide, which is not the highest dose available,' she noted. 'A better comparison would be with the highest dose of semaglutide (2.4 mg) but that data is not available.'
Nevertheless, the study's assessment of the simultaneous goals is a strength, Srinivasan said.
'This particular study looked at overall therapeutic targets, both standard and intensive, which was interesting to see compared to the usual A1c and weight only results.'
The SURPASS-2 trial was funded by Eli Lilly. Leite reported having received consulting fees from BIAL. Srinivasan had no disclosures to report. Lead image: Nndanko/Dreamstime
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
3 days ago
- New York Post
Mounjaro boobs? Weight loss drug can shrink breast cancer tumors, says new study
Turns out that GLP-1 drugs aren't just slimming waistlines — they're shrinking tumors, too. A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting injected with tirzepatide, which is sold as Mounjaro for diabetes and Zepbound for obesity. 'Obesity is a significant risk factor for breast cancer,' said study author Amanda Kucinskas, a Ph.D. candidate at the University of Michigan. 4 Breast cancer is the most commonly diagnosed cancer in women worldwide, excluding skin cancers. okrasiuk – 'And while it is very preliminary data, our studies in mice suggest that these new anti-obesity drugs may be a way to reduce obesity-associated breast cancer risk or improve outcomes.' Tirzepatide is part of a class of GLP-1 drugs, like Ozempic and Wegovy, that reduce appetite by mimicking the GLP-1 hormone the body naturally produces after eating. Tirzepatide also mimics the effects of GIP, a gut hormone that stimulates insulin release and influences fat storage and appetite. For the new study, 16 young mice with breast cancer were fattened up and kept in a warm home to encourage obesity. 4 Tirzepatide is sold as Mounjaro for diabetes and Zepbound for obesity. K KStock – The mice were then given tirzepatide or a placebo every other day for 16 weeks. The researchers measured their tumor volumes twice a week, finding that as the mice shed the pounds and the fat stored in their livers, their tumors shrank accordingly. The findings were presented this month at ENDO 2025, the Endocrine Society's annual meeting. 'While these are very preliminary results, they suggest that this new anti-obesity drug may also have a beneficial impact on breast cancer outcomes,' Kucinskas said. 4 A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting injected with tirzepatide. romaset – Breast cancer is the most commonly diagnosed cancer in women worldwide, besides skin cancer. One in eight American women will likely be diagnosed with it at some point. There are several reasons why obesity is a major risk factor for breast cancer. 'Obesity causes widespread inflammation throughout the entire body, deregulating the balance of cell growth patterns, body defenses and the gut microbiome,' Dr. Sue Decotiis — an NYC-based medical weight loss doctor, who was not involved in the new study — told The Post. 'Even a modest reduction of fat could have an important anti-inflammatory effect.' Excess abdominal fat can also lead to higher estrogen levels. Hormonal imbalances promote breast cancer development, Decotiis said. Plus, obesity is often associated with higher-than-normal levels of insulin in the blood, which can stimulate the production of estrogen in fat tissue. 'In my clinical weight loss practice, all secondary benefits from GLP-1 drugs occurred in patients who lost not weight, but a significant reduction in fat,' Decotiis said. 4 Obesity is a major risk factor for breast cancer, particularly in postmenopausal women. Choi_ Nikolai – Although GLP-1 meds have been hailed as 'wonder drugs,' there are risks associated with them. Side effects can include gastrointestinal distress and, less often, hair loss and skin pain. Blindness and behavioral changes can occur in very rare cases. Decotiis noted that tirzepatide is often better tolerated than the other meds because it can cause less nausea and vomiting while also spurring more weight loss. Meanwhile, research continues on the potential for these drugs to slow the progression of Alzheimer's disease, improve sleep apnea, reduce alcohol cravings and treat liver disease, among other conditions. 'Hold on to your hats and buckle up as this category of drug grows and we see more of their wide range of positive effects and learn more about their mechanisms,' Decotiis said.
Yahoo
3 days ago
- Yahoo
The 3 Things That Matter for Eli Lilly Now
Key Points Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral GLP-1 candidate will soon report key phase 3 results in weight management. The drugmaker's shares look expensive, but the premium is justified given Lilly's prospects. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong clinical and regulatory progress, as well as robust financial results, the drugmaker has routinely impressed Wall Street. Lilly has experienced a slowdown this year, and its shares have underperformed broader equities. Still, the company could turn things around and return to its market-beating ways, especially if it can execute effectively on several fronts. Let's discuss three critical areas of its business to pay close attention to right now. 1. Tirzepatide's progress It has now been more than three years since the U.S. Food and Drug Administration (FDA) first approved tirzepatide, the medicine Eli Lilly markets as Mounjaro for treating diabetes and as Zepbound for weight management. The two brands have been generating mouthwatering sales. Each racked up billions of dollars in revenue last quarter. Mounjaro and Zepbound will continue to be crucial to Eli Lilly's progress. Here are two key things to watch. First, how quickly are their sales continuing to grow? Analysts will be closely monitoring these numbers for the foreseeable future. Image source: Getty Images. Second, will they earn label expansions? Tirzepatide has already aced other phase 3 studies, such as in cutting the risk of diabetes in patients who were overweight (or obese) and prediabetic. Regulatory authorities are now reviewing it in helping prevent heart failure in obese patients. Tirzepatide is being investigated in late-stage trials as a potential treatment for psoriasis and psoriatic arthritis in combination with other medicines. It's also being tested in mid-stage studies in metabolic dysfunction-associated steatohepatitis (MASH). So the therapy could earn many more label expansions, which will help boost its already fast-growing sales. It's a good idea to monitor Lilly's developments related to this drug. 2. Orforglipron's weight management results In April, Eli Lilly posted strong phase 3 results for its next-gen GLP-1 medicine, orforglipron, in diabetes patients. Orforglipron is a particularly important pipeline candidate to follow, because it could be one of the first oral GLP-1 therapies to hit the market. Some patients don't like needles and would vastly prefer a daily oral option over the current subcutaneously administered options. And while Lilly's recent phase 3 win for orforglipron in diabetes was significant, investors will be especially interested in the medicine's performance in weight management.
Yahoo
3 days ago
- Yahoo
5 Things to Do Before Bed to Help Lower Blood Pressure, According to a Cardiologist
Reviewed by Dietitian Karen Ansel, M.S., RDN Maintaining healthy blood pressure is about more than keeping your doctor happy at your checkup. It is a key part of reducing your risk of heart disease, stroke and other serious health issues. When thinking about ways to support healthy blood pressure, a heart-healthy diet and exercise may come to mind, which isn't wrong. But it's not just about what you do by day. Your nighttime routine plays a bigger role in your heart health than you might think. That's right! Getting ready for bed might feel like an ordinary part of your day, but did you know certain bedtime steps may be powerful medicine for better blood pressure? We spoke with Mary Branch, M.D., a cardiologist at Cone Health in Greensboro, North Carolina, about how to make the most of those precious pre-sleep moments to support healthy blood pressure. And trust us, it's easier than you'd expect (no burpees required!). Before you hit the pillow tonight, try these five simple yet effective tips to give your blood pressure a little extra love. 1. Limit Alcohol For some people, unwinding at the end of the day might include sipping on a boozy nightcap. However, if you have high blood pressure, cutting back on alcohol is especially important, says Branch. 'For women, it is recommended to drink no more than one drink per day, and two for men,' she says. While alcohol may feel relaxing in the moment, it can actually make it harder to manage your blood pressure over time. Even small amounts can interfere with medications or put additional strain on your heart and blood vessels. And the more you drink, the higher your blood pressure rises. The link is so strong that one study found that each additional daily drink a person had significantly increased their systolic and diastolic blood pressure. The good news? By swapping that nightcap for something like herbal tea, such as chamomile tea, or simply sticking to water, you're doing your body a huge favor. In addition to helping promote more stable blood pressure, you'll give your body a hydration boost, too. Just go for caffeine-free beverage options, as caffeine may make it hard to sleep. 2. Remember Your Medication 'If you're prescribed medications to treat hypertension, it is recommended that you take these medications each day,' says Branch. This includes medications you may need to take before bed. Yes, even on nights when you feel too tired to open a pill bottle. Adhering to prescribed hypertension medications is crucial for effectively managing blood pressure and reducing the risk of serious health complications, such as heart attacks and strokes. Consistency is key, as these medications work best when maintained at steady levels in your system. Skipping a dose can disrupt this balance and potentially hinder progress. Incorporating daily reminders, such as setting an alarm or using a pill organizer, can help ensure you take your medications on time. Simple steps like keeping your medications within reach, like near your bedside or in a spot you frequent, can make it easier to stay on track—even on those long days when opening a pill bottle feels like a chore. 3. Practice Mindfulness Branch suggests that practicing meditation and mindfulness may be a helpful bedtime habit for healthy blood pressure. 'This can help bring down your stress level and your blood pressure along with it,' she says. 'Furthermore, it can help you with getting a good night's rest, which is also important for reducing blood pressure.' Scientific data supports these recommendations. Research highlights the link between stress and higher blood pressure, illustrating the importance of addressing stress for overall health. By taking small but intentional steps toward relaxation before bed, you can set yourself up for restful sleep and a healthier tomorrow. Some additional ways to manage stress before bed include practicing yoga or gentle stretching to ease muscle tension, journaling to clear your mind, and creating a calming bedtime environment by reducing noise and dimming lights. Establishing a consistent bedtime routine can further signal to your body that it's time to wind down, creating a seamless transition to restful sleep. 4. Avoid High-Sodium Snacks Late-night snacking can be tempting. But if you're aiming to support healthy blood pressure, it's crucial to steer clear of high-sodium foods before bed. Consuming salty snacks like chips, canned soups or pretzels may cause your body to retain water. This can increase the pressure on your blood vessels. So, keeping your sodium intake in check, especially before sleep, may help stabilize your blood pressure overnight and promote better overall cardiovascular health. Opt for low-sodium snacks like fresh fruit, unsalted nuts or air-popped popcorn. They'll satisfy your evening cravings without compromising your blood pressure. 5. Keep Your Bedroom Cool, Dark and Comfortable Creating the right sleep environment can have a surprising impact on healthy blood pressure levels. A cool, dark, comfortable bedroom not only promotes better sleep but also may support heart health by encouraging quality sleep. Conversely, data suggests that poor sleep can lead to elevated blood pressure over time. To keep your bedroom comfortable, ensure your room is dark, quiet and cool. Eliminating distractions such as bright lights or loud noises and investing in a supportive mattress and pillow may also encourage deeper, more restorative sleep. These small adjustments may help your body relax and recover from the day, contributing to better blood pressure regulation. Our Expert Take Certain healthy bedtime habits can have a significant impact on your blood pressure. And developing these habits doesn't have to feel overwhelming or complicated. Simple strategies like limiting alcohol, taking your blood pressure medication, practicing mindfulness, avoiding high-sodium snacks and creating a comfortable sleep environment can all help promote better blood pressure. In addition to tried-and-true methods for supporting blood pressure, like exercise and a healthy diet, these easy, proactive steps can help lower blood pressure and improve heart health. Remember, the path to better well-being often starts with small, intentional changes. By prioritizing these pre-sleep practices, you'll not only support your blood pressure but also enhance your overall quality of life, one restful night at a time. Read the original article on EATINGWELL
